We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
+4.77%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$646M
AUM Growth
+$38.6M
Cap. Flow
+$20.8M
Cap. Flow %
3.22%
Top 10 Hldgs %
64.44%
Holding
59
New
19
Increased
16
Reduced
8
Closed
14

Top Buys

Rank Stock Value
1
EXEL icon
Exelixis
EXEL
+$29.4M
2
TSRO
TESARO, Inc.
TSRO
+$21.1M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15.5M
4
ESPR
Esperion Therapeutics
ESPR
+$14.5M
5
BOLD
Audentes Therapeutics, Inc
BOLD
+$8.94M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$22.7M
2
BMY icon
Bristol-Myers Squibb
BMY
+$21.7M
3
SHPG
Shire pic
SHPG
+$20.8M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$14.9M
5
CORT icon
Corcept Therapeutics
CORT
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 60.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KURA icon
26
Kura Oncology
KURA
$901M
$6.94M 1.07%
381,459
+29,504
+8% +$500K
SGEN
27
DELISTED
Seagen Inc. Common Stock
SGEN
$6.78M 1.05%
102,187
-260,787
-72% -$14.9M
CORT icon
28
Corcept Therapeutics
CORT
$9.78B
$5.27M 0.82%
335,177
-710,019
-68% -$12.4M
DCPH
29
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$5.11M 0.79%
+129,800
New +$3.82M
AKRX
30
DELISTED
Akorn Inc
AKRX
$4.47M 0.69%
269,503
-235,000
-47% -$3.6M
ACOR
31
DELISTED
Acorda Therapeutics
ACOR
$4.26M 0.66%
+1,237
New +$3.79M
SLGL icon
32
Sol-Gel Technologies
SLGL
$261M
$3.98M 0.62%
51,537
-250
-0.5% -$22.9K
ONCS
33
DELISTED
OncoSec Medical Incorporated
ONCS
$3.61M 0.56%
11,883
+2,500
+27% +$876K
ZSAN
34
DELISTED
Zosano Pharma Corporation
ZSAN
$2.86M 0.44%
20,000
– –
NEOS
35
DELISTED
Neos Therapeutics, Inc
NEOS
$2.37M 0.37%
+378,961
New +$2.83M
DNTH icon
36
Dianthus Therapeutics
DNTH
$5.71B
$2.02M 0.31%
+9,375
New +$2.12M
WHWK
37
Whitehawk Therapeutics
WHWK
$183M
$1.24M 0.19%
+19,925
New +$1.2M
ARAV
38
DELISTED
Aravive, Inc. Common Stock
ARAV
$1.01M 0.16%
+83,333
New +$858K
TGTX icon
39
TG Therapeutics
TGTX
$8.53B
$949K 0.15%
+72,200
New +$993K
MTEM
40
DELISTED
Molecular Templates, Inc.
MTEM
$902K 0.14%
+11,492
New +$1.3M
KNSA icon
41
Kiniksa Pharmaceuticals
KNSA
$4.89B
$680K 0.11%
+39,180
New +$709K
CRBP icon
42
Corbus Pharmaceuticals
CRBP
$168M
$678K 0.11%
+4,476
New +$813K
TGTX icon
43
CALL
TG Therapeutics
TGTX
$8.53B
$658K 0.1%
+50,000
New +$688K
MDWD icon
44
MediWound
MDWD
$186M
$308K 0.05%
+6,368
New +$274K
TECX
45
Tectonic Therapeutic
TECX
$578M
$286K 0.04%
+833
New +$300K
ADVM
46
DELISTED
Adverum Biotechnologies
ADVM
– –
-50,118
Closed -$2.91M
ARWR icon
47
Arrowhead Research
ARWR
$12B
– –
-1,114,097
Closed -$8.03M
BMRN icon
48
BioMarin Pharmaceuticals
BMRN
$11.6B
– –
-259,235
Closed -$22.7M
BMY icon
49
Bristol-Myers Squibb
BMY
$128B
– –
-342,399
Closed -$21.7M
HRTX icon
50
Heron Therapeutics
HRTX
$86.9M
– –
-409,000
Closed -$11.3M
1
2
3

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Nexthera Capital held 59 positions worth $646M, up 6.4% from $607M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Nexthera Capital deployed $20.8M of net new capital in Q2 2018, opening 19 new positions and adding to 16 existing holdings. Its largest new stake was Exelixis: 1,421,600 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 63% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $14.9M trimmed.

  • Nexthera Capital's largest Q2 2018 buy was Exelixis: 1,421,600 shares worth $30.6M.
  • Nexthera Capital added most to Dova Pharmaceuticals, Inc. Common Stock in Q2 2018, an estimated $6.87M increase.
  • Nexthera Capital's biggest Q2 2018 reduction was Seagen Inc. Common Stock, cutting an estimated $14.9M.
  • Nexthera Capital fully exited BioMarin Pharmaceuticals in Q2 2018, selling an estimated $22.7M.
  • Nexthera Capital's ten largest holdings make up 64% of its $646M portfolio in Q2 2018.
  • Nexthera Capital opened 19 new positions and closed 14 in Q2 2018.
  • Nexthera Capital's portfolio value rose 6.4% quarter-over-quarter to $646M.

Based on Nexthera Capital's 13F filing for Q2 2018, filed 14 Aug 2018.